AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Hemispherian Raises Seed Funding For Novel Cancer Therapeutics

May 03, 2022•over 3 years ago

Round Type

seed

Oslo

Description

Hemispherian AS ("Hemispherian" or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, is delighted to announce the closure of its successful seed financing. The oversubscribed round raised NOK 12.5M (USD 1.4M). The proceeds will support the company's drug development activities, expand its preclinical pipeline and move its lead therapeutic compounds towards clinical development.

Company Information

Company

Hemispherian As

Location

Oslo, Oslo, Norway

About

Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company's lead compound, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma multiforme, a deadly cancer of the central nervous system and the leading cause of death by disease in children. Hemispherian is further focused on developing a companion diagnostic tool to support patient selection for optimal therapeutic response to GLIX1. Hemispherian is based in Oslo, Norway. For more information, visit www.hemispherian.com.

Company News

(5 articles)

Tue, 05 Aug 2025 07:00:00 GMT

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1 - Morningstar

Tue, 01 Jul 2025 07:00:00 GMT

Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma - Yahoo Finance

Thu, 24 Nov 2022 08:00:00 GMT

Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics - PR Newswire

Tue, 03 May 2022 07:00:00 GMT

Hemispherian raises seed funding for novel cancer therapeutics - BioSpace

Tue, 05 Aug 2025 07:00:00 GMT

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1 - The Malaysian Reserve

FundzWatch™ Score

Medium Activity